Elevated circulating FGF21 levels have been associated with conditions characterized by hepatic insulin-resistance (metabolic syndrome [37], nonalcoholic fatty liver disease (NAFLD) [38], and T2DM [39]). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.